Etoposide (VP-16), ifosfamide/mesna, and cisplatin chemotherapy for advanced and recurrent carcinoma of the cervix
| Autor: | Daniel C. Kredentser |
|---|---|
| Rok vydání: | 1991 |
| Předmět: |
Adult
medicine.medical_specialty medicine.medical_treatment Urology Uterine Cervical Neoplasms Phases of clinical research Antineoplastic Combined Chemotherapy Protocols medicine Humans Ifosfamide Cervix Etoposide Aged Mesna Cisplatin Chemotherapy business.industry Carcinoma Obstetrics and Gynecology Middle Aged Hematologic Diseases Surgery medicine.anatomical_structure Oncology Toxicity Female Neoplasm Recurrence Local business medicine.drug |
| Zdroj: | Gynecologic Oncology. 43:145-148 |
| ISSN: | 0090-8258 |
| Popis: | A Phase II study of VP-16 (etoposide), ifosfamide/mesna, and cisplatin (VIP) in advanced and recurrent carcinoma of the cervix was initiated March 1989. VP-16, 75 mg/m2, ifosfamide, 1.0 g/m2, and cisplatin, 25 mg/m2, were administered intravenously daily for 3 consecutive days, every 28 days to a maximum of six cycles. Fourteen patients were entered on protocol. Eight patients had objective responses, all complete. Response duration ranged from 7+ to 24+ months. The chemotherapy was well-tolerated. Hematologic toxicity was the major toxicity and was manageable. VIP appears to be active in advanced carcinoma of the cervix. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|